LEAH Labs
Living therapies for pets first, and their people next
LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective "full stack" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.
Active Founders
Wesley Wierson, Founder
I am a scientist and entrepreneur seeking to apply my expertise in gene editing towards solving consumer level problems in society, first focused on building curative cancer therapies for pets, and eventually their owners.
I believe that gene editing technology has the power to rewrite human history, and it is paramount that scientists apply gene editing with precise control over the outcomes, both at the molecular and the societal impact levels.
